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The UK Biobank is made up of approximately 500,000 participants (of which 94% are of 
self-reported European-ancestry), aged 40 to 69 at recruitment between 2006 and 2010 across 
22 assessment centres in the UK. Ethical approval for the UK Biobank study was obtained 
from the North West Multicenter Research Ethics Committee. All participants provided 
written informed consent. In this study, UK Biobank data was accessed through application 
29202 and follow up was performed to 31 March 2020 or the date of death. Participant 
information was available for genotype, clinical measurements, biological assays, and self-
reported health behaviours, with further linkage to electronic health records (1). To derive our 
initial analytic sample, we excluded participants having non-European ancestry (self-report or 
judged by genetics), low call rate or excess heterozygosity (>3 standard deviations from the 
mean) as described previously (2). We included only one of each set of related participants 
(third-degree relatives or closer). We also excluded participants without a valid HbA1c 
measurement. 
HbA1c was measured in packed red blood cells using the Bio-Rad Variant II Turbo analyser 
(Bio-Rad Laboratories, Inc), which employs a High Performance Liquid Chromatography 
method. Results are expressed in mmol/mol units, with an analytical range of 15-
184mmol/mol. 
Our analyses only included participants who were judged as unlikely to have any type of 
diabetes mellitus. Possible diabetes was identified based on self-reported information, 
hospital episode statistics, and information on prescription medication as previously 
described (3). Only those judged as diabetes ‘unlikely’ were included in the analysis. 
Additionally, we excluded from analysis all those with residual HbA1c (defined below) above 
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47.5 mmol/mol (6.5%), the threshold defined by the American Diabetes Association as a 
diagnostic criterion for diabetes (4). 
International Classification of Diseases 9th Revision (ICD-9) codes 410-414, and ICD-10 
codes I20-I25 were used to identify incident coronary heart disease cases. 
 
Linear Mendelian randomization 
The ratio of coefficients method was used to perform Mendelian randomization analyses that 
assumed a linear relationship between genetically-proxied average blood glucose levels and 
risk of incident coronary heart disease (CHD) (5). This represents the association of the 
average blood glucose level allele score with CHD divided by the association of the allele 
score with HbA1c (6). We used linear regression to estimate the association of the allele score 
with HbA1c, incorporating age, sex, principal components 1-10 of genetic ancestry, 
genotyping chip and assessment centre as covariates.  
We calculated the proportion of variance in HbA1c explained by the allele score and its F-
statistic to estimate instrument strength (7). We used Cox proportional hazard regression to 
estimate the association of the allele score with CHD risk, incorporating sex, principal 
components 1-10 of genetic ancestry, genotyping chip and assessment centre as covariates. 
Age was used as the time variable in the time-to-event analyses. In sensitivity analyses, each 
variant in the allele score was considered as a separate instrumental variable using Mendelian 
randomization methods that differ in their requisite assumptions on the inclusion of 
pleiotropic variants: fixed-effects inverse-variance weighted, random-effects inverse-variance 
weighted, Egger, weighted median, contamination-mixture and PRESSO Mendelian 
randomization (8). An intercept term in the Egger method that differs from zero can be used 
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to provide evidence of directional pleiotropy (9). Statistics measuring heterogeneity in the 
Mendelian randomization estimates generated by different variants were further calculated to 
measure potential pleiotropy (10). 
 
Non-linear Mendelian randomization 
The fractional polynomial method was used to investigate for a non-linear relationship 
between genetically-proxied average blood glucose levels and risk of incident CHD (11-13). 
In this approach, we stratified the population into trigintiles (30 equal groups) based on 
residual HbA1c, which is defined as a participant’s HbA1c minus the genetic contribution to 
HbA1c from the average blood glucose level allele score. Thus, we aimed to compare 
individuals in the population who would have a similar average blood glucose levels (in the 
same trigintile stratum) if they also had the same genetic predisposition. Stratifying on HbA1c 
itself would introduce collider bias and potentially distort estimates, as average blood glucose 
levels may be on the causal pathway from the genetic variants to CHD (13; 14). For each 
trigintile of the population, a linear Mendelian randomization estimate for the association of 
genetically-proxied HbA1c with CHD was calculated using the ratio of coefficients method, 
as detailed above (6). A meta-regression of the linear Mendelian randomization estimates 
obtained for each trigintile against the mean HbA1c in that centile was then performed using a 
flexible semiparametric framework (11; 13). We used a fractional polynomial test to 
investigate whether a non-linear model fit this meta-regression better than a linear model (11-
13). A significant p value for this test is evidence against the null hypothesis that the linear 
model fits the data as well as the best-fitting fractional polynomial model. Hence a significant 
p value suggests that a non-linear model fits the data better than a linear model. Pre-specified 
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subgroup analyses considering males and females separately were also performed to 
investigate potential sex-specific effects. 
 
Multivariable Mendelian randomization 
Associations of the allele score were assessed using two-sample Mendelian randomization 
implemented by the inverse-variance weighted method with a random-effects model. Genetic 
associations with two-hour (post-load) glucose, fasting glucose, and fasting insulin were 
obtained from the MAGIC consortium (15; 16). Genetic associations with low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides 
were obtained from the Global Lipids Genetics Consortium (GLGC) (17). Multivariable 
Mendelian randomization was performed by first creating an allele score for genetically-
proxied LDL-cholesterol using genetic associations with LDL-cholesterol from the GLGC as 
weights. We then adjusted for genetically-proxied LDL-cholesterol in the calculation of the 
stratum-specific estimates, before combining in the non-linear model as described above.  
 
Exclusion of variants associated with LDL-cholesterol 
As a further sensitivity analysis, we performed Mendelian randomization analysis that 
excluded variants associated with LDL-cholesterol at p<0.01. 
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ESM Table 1. The genetic variants used as instruments for average blood glucose levels, and their associations with type 2 diabetes liability and HbA1c. 
Genetic variants were selected based on their association with type 2 diabetes liability (p<5x10-8) in a genome-wide association study of 228,499 cases and 
1,178,783 controls (79% European ancestry) that included UK Biobank participants and their association with HbA1c (p<0.001 and concordant direction of 
association) in an independent study of 100,880 European ancestry participants (no overlap with UK Biobank) that were free of diabetes mellitus (as defined by 
physician diagnosis, medications, or fasting glucose ≥7 mmol/L). 













Beta (log odds ratio) 
Standard 
error 




rs10923360 1 118166877 T C 0.3299 0.0286 0.004 5.99E-13 0.007 0.0019 1.73E-04 
rs3020781 1 155269776 G A 0.3719 0.0294 0.0043 7.29E-12 0.0069 0.002 4.53E-04 
rs340874 1 214159256 C T 0.4991 0.0543 0.0039 6.47E-45 0.0079 0.0016 3.65E-07 
rs1260326 2 27730940 C T 0.5805 0.0625 0.0039 2.16E-57 0.0059 0.0017 3.69E-04 
rs17334919 2 43707385 T C 0.0916 -0.1207 0.0075 2.27E-58 -0.012 0.003 6.44E-05 
rs10184004 2 165508389 T C 0.4049 -0.0636 0.0041 4.39E-54 -0.0063 0.0018 3.45E-04 
rs11708067 3 123065778 G A 0.2229 -0.0804 0.005 1.63E-57 -0.013 0.0019 1.42E-12 
rs9873519 3 124921457 T C 0.4712 0.0373 0.0038 2.53E-22 0.0071 0.0019 1.39E-04 
rs16851397 3 141134818 G A 0.0656 -0.0684 0.0093 2.17E-13 -0.014 0.0037 1.25E-04 
rs8192675 3 170724883 C T 0.3167 -0.0452 0.0042 3.85E-27 -0.011 0.0017 1.38E-11 
rs9859406 3 185534482 A G 0.3524 0.1117 0.004 2.01E-169 0.0064 0.0019 5.95E-04 
rs1996617 4 52798624 C T 0.3914 0.0289 0.004 6.54E-13 0.0078 0.002 7.35E-05 
rs735949 4 185716232 C T 0.1332 -0.0555 0.0064 2.78E-18 -0.0098 0.0022 6.58E-06 
rs6878122 5 76427311 A G 0.7058 -0.0517 0.0045 2.00E-30 -0.0091 0.0019 1.05E-06 
rs10440833 6 20688121 T A 0.7028 -0.1286 0.0041 4.51E-215 -0.01 0.002 1.65E-07 
rs3117189 6 32033944 G A 0.8469 0.0573 0.0057 3.87E-24 0.013 0.0031 1.61E-05 
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rs679582 6 139831180 A G 0.5485 -0.0262 0.0039 2.28E-11 -0.009 0.0019 1.37E-06 
rs2191349 7 15064309 T G 0.5668 0.067 0.0038 2.57E-71 0.0086 0.0017 2.09E-07 
rs2267716 7 30716643 C T 0.2741 -0.0364 0.0044 2.21E-16 -0.0074 0.0022 6.66E-04 
rs1799884 7 44229068 T C 0.1716 0.0553 0.005 9.45E-29 0.029 0.0026 1.06E-29 
rs13266634 8 118184783 T C 0.3186 -0.1024 0.0041 4.23E-136 -0.015 0.0017 4.53E-20 
rs4237150 9 4290085 C G 0.4292 0.0433 0.0037 6.98E-31 0.0064 0.0018 2.77E-04 
rs10811661 9 22134094 C T 0.2442 -0.1471 0.0048 9.59E-206 -0.014 0.0024 4.14E-09 
rs505922 9 136149229 C T 0.3613 0.0413 0.0039 1.61E-26 0.0072 0.0017 1.39E-05 
rs11257655 10 12307894 T C 0.2956 0.0946 0.0056 1.44E-63 0.0082 0.0021 7.51E-05 
rs1111875 10 94462882 T C 0.451 -0.0928 0.0038 1.44E-128 -0.0068 0.0016 1.20E-05 
rs17747324 10 114752503 C T 0.2198 0.2493 0.005 <1.00E-299 0.015 0.0023 6.12E-11 
rs2403221 11 9852475 A G 0.5516 0.0263 0.0041 1.16E-10 0.0065 0.0019 4.88E-04 
rs757110 11 17418477 A C 0.6296 -0.0599 0.0039 4.59E-52 -0.0056 0.0017 7.25E-04 
rs174541 11 61565908 C T 0.3493 -0.0277 0.0041 2.39E-11 -0.0076 0.002 1.12E-04 
rs1552224 11 72433098 C A 0.1452 -0.0917 0.0058 2.53E-56 -0.012 0.0021 1.61E-08 
rs10830963 11 92708710 G C 0.3057 0.0731 0.0042 1.29E-66 0.02 0.002 2.23E-23 
rs2732480 12 48736303 A C 0.4201 -0.0314 0.0042 6.40E-14 -0.012 0.002 2.00E-09 
rs12910361 15 77782335 G A 0.614 0.0686 0.004 5.19E-65 0.008 0.002 4.78E-05 
rs2290202 15 91512267 T G 0.2533 0.0576 0.005 6.31E-31 0.011 0.0029 1.29E-04 
rs6600191 16 295795 C T 0.2491 -0.0428 0.0046 2.97E-20 -0.01 0.0026 5.88E-05 
rs1421085 16 53800954 C T 0.367 0.1182 0.004 1.29E-189 0.0085 0.0017 2.89E-07 
rs2297508 17 17715317 G C 0.5583 -0.0305 0.004 2.39E-14 -0.0068 0.0019 2.64E-04 
rs12603589 17 65825248 C T 0.3128 0.0421 0.0046 1.06E-19 0.0075 0.0023 9.94E-04 
rs10408179 19 46157004 C T 0.4257 -0.0517 0.0039 1.86E-40 -0.006 0.0017 2.93E-04 
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ESM Table 2. Baseline characteristics of UK Biobank participants. Individuals with possible diabetes mellitus were excluded. CHD: coronary 
heart disease; LDL-C: low-density lipoprotein cholesterol; SD: standard deviation. 
 Overall Males Females No CHD event CHD event 
Possible diabetes 
mellitus (excluded) 
Number of participants (n) 324,830 145,472 179,358 318,824 6006 26,562 
Mean (SD) age at survey / years 56.9 (8.0) 57.1 (8.2) 56.8 (7.9) 56.9 (8.1) 60.5 (6.9) 60.1 (7.1) 
Number (%) of females 179,358 (55.2) - - 177,758 (55.8) 1600 (26.6) 10,493 (39.5) 
Mean (SD) body mass index / kg/m2 27.0 (4.5) 27.5 (3.9) 26.7 (4.9) 27.0 (4.5) 28.0 (4.3) 31.6 (5.8) 
Mean (SD) HbA1c / mmol/mol 34.8 (3.6) 34.8 (3.9) 34.9 (3.6) 34.8 (3.6) 35.9 (3.7) 49.9 (14.0) 
Mean (SD) HbA1c / % 5.3 (0.3) 5.3 (0.3) 5.3 (0.3) 5.3 (0.3) 5.4 (0.3) 6.7 (1.3) 
Mean (SD) LDL-cholesterol / mmol/L 3.6 (0.8) 3.6 (0.8) 3.7 (0.9) 3.6 (0.8) 3.7 (1.0) 3.0 (0.9) 
Mean (SD) systolic blood pressure / mmHg 137.3 (18.6) 140.6 (17.4) 134.7 (19.2) 137.2 (18.6) 144.8 (19.6) 142.1 (18.0) 
Mean (SD) diastolic blood pressure / mmHg 81.9 (10.1) 84.0 (10.0) 80.3 (9.9) 81.9 (10.1) 84.5 (10.7) 82.3 (10.3) 
Number of current smokers (%) 33,052 (10.2) 17,566 (12.1) 15,486 (8.6) 31,834 (10.0) 1218 (20.3) 3213 (12.1) 





ESM Table 3. Results of non-linear Mendelian randomization analyses investigating the association of genetically-proxied average blood 
glucose levels with incident coronary heart disease in the total analytic sample (all) and in quintiles of the sample based on residual HbA1c. 
Hazard ratios are given per 1 mmol/mol increase in genetically-proxied HbA1c. HR: hazard ratio. 
Strata 
Overall Males Females 
Mean HbA1c 
(mmol/mol / %) 
HR (95% CI) 
Mean HbA1c 
(mmol/mol / %) 
HR (95% CI) 
Mean HbA1c 
(mmol/mol / %) 
HR (95% CI) 
All 34.8 / 5.3% 
1.11 (1.05-1.18) 
p=2×10-4 
34.8 / 5.3% 
1.12 (1.05-1.19) 
p=4×10-4 
34.9 / 5.3% 
1.08 (0.96-1.20) 
p=0.20 
Quintile 1 29.8 / 4.9% 
1.18 (1.01-1.37) 
p=0.037 
29.8 / 4.9% 
1.22 (1.03-1.45) 
p=0.023 
29.9 / 4.9% 
1.07 (0.78-1.48) 
p=0.67 
Quintile 2 33.0 / 5.2% 
1.10 (0.95-1.26) 
p=0.21 
33.0 / 5.2% 
1.13 (0.96-1.32) 
p=0.13 
33.1 / 5.2% 
1.05 (0.77-1.42) 
p=0.77 
Quintile 3 34.8 / 5.3% 
1.27 (1.11-1.45) 
p=4×10-4 
34.8 / 5.3% 
1.22 (1.05-1.41) 
p=0.010 
34.9 / 5.3% 
1.28 (0.98-1.66) 
p=0.066 
Quintile 4 36.6 / 5.5% 
1.10 (0.98-1.24) 
p=0.12 
36.6 / 5.5% 
1.08 (0.95-1.24) 
p=0.24 
36.7 / 5.5% 
1.15 (0.91-1.45) 
p=0.26 
Quintile 5 39.8 / 5.8% 
1.01 (0.91-1.12) 
p=0.90 
39.8 / 5.8% 
1.04 (0.92-1.17) 
p=0.53 







ESM Table 4. Results of linear Mendelian randomization (MR) sensitivity analyses investigating the association of genetically-proxied average 
blood glucose levels with incident coronary heart disease. Hazard ratios are given per 1mmol/mol increase in genetically-proxied HbA1c. HR: 
hazard ratio. 
Method Hazard ratio (95% CI) p value 
Inverse-variance weighted method (fixed-effects) 1.11 (1.05, 1.18) 2×10-4 
Inverse-variance weighted method (random-effects) 1.11 (1.03, 1.21) 0.007 
Weighted median method 1.12 (1.03, 1.23) 0.009 
MR-Egger method 1.11 (0.91, 1.35) 0.30 
(intercept) 0.000 (-0.022, 0.022) 0.97 
MR-PRESSO method 1.10 (1.02, 1.18) 0.014 
Contamination mixture method 1.15 (1.06, 1.24) 4×10-4 
Heterogeneity test Statistic p value 
Q statistic 73.1 8×10-4 
I2 statistic 46.7%  
 




ESM Table 5. Results of Mendelian randomization (MR) analyses investigating the association of genetically-proxied average blood glucose 
levels with glycaemic and lipid traits. Estimates are given per 1mmol/mol increase in genetically-proxied HbA1c. 
Trait Estimate (95% CI) p value 
Fasting glucose (mmol/L) 1.72 (1.36, 2.07) <0.001 
Two-hour glucose (mmol/L) 3.13 (1.95, 4.32) <0.001 
Fasting insulin (nmol/L, log-transformed) -0.133 (-0.347, 0.080) 0.22 
Low-density lipoprotein-cholesterol (SD units) 0.433 (0.034, 0.831) 0.033 
High-density lipoprotein-cholesterol (SD units) -0.031 (-0.378, 0.316) 0.86 







ESM Figure 1. Genetic associations of the instrument variants with HbA1c (mmol/mol units) 
in male and female participants of the UK Biobank respectively, obtained from analyses 
performed by the Neale Lab (available at http://www.nealelab.is/uk-biobank). Association 




ESM Figure 2. Scatter plot of genetic association estimates for HbA1c and incident coronary 
heart disease (CHD) risk. The gradient of the blue line depicts the random effects inverse-
variance weighted Mendelian randomization estimate. For each variant (N=40), the genetic 
association and its 95% confidence interval with the exposure (HbA1c; x-axis) and with the 





ESM Figure 3. Scatter plots of genetic association estimates for HbA1c and glycaemic and 






ESM Figure 4. Multivariable Mendelian randomization (adjusting for genetically-proxied 
low-density lipoprotein cholesterol) investigating the relationship between genetically-
proxied average blood glucose levels, as measured by HbA1c, and risk of incident coronary 
heart disease in individuals without diabetes mellitus in males and females combined. The x-
axis depicts HbA1c levels in mmol/mol. The y-axis depicts the hazard ratio for coronary heart 
disease with respect to the reference. Reference is set to an HbA1c of 30mmol/mol (4.9%). 
The grey lines represent the 95% confidence intervals. The fractional polynomial test is a 
goodness-of-fit test that assesses whether any improvement of fit when using a non-linear 
function to model the association, as compared to a linear function, is greater than would be 
expected due to chance (a significant p value indicates that a non-linear model is preferred to 




ESM Figure 5. Non-linear Mendelian randomization investigating the relationship between 
genetically-proxied average blood glucose levels, as measured by HbA1c, and risk of incident 
coronary heart disease in individuals without diabetes mellitus in males and females 
combined. The five variants that associated with low-density lipoprotein cholesterol at 
p<0.01 (rs1260326, rs10184004, rs11708067, rs505922 and rs174541) were excluded. Three 
of these variants (s10184004, rs505922 and rs174541) associated with low-density 
lipoprotein cholesterol at p<5x10-8). The x-axis depicts HbA1c levels in mmol/mol. The y-
axis depicts the hazard ratio for coronary heart disease with respect to the reference. 
Reference is set to an HbA1c of 30mmol/mol (4.9%). The grey lines represent the 95% 
confidence intervals. The fractional polynomial test is a goodness-of-fit test that assesses 
whether any improvement of fit when using a non-linear function to model the association, as 
compared to a linear function, is greater than would be expected due to chance (a significant 
p value indicates that a non-linear model is preferred to a linear model). 
 
